Demographic and clinical data for the patients according to liver fibrosis.

<p><i>Abbreviations</i>: ART: antiretroviral therapy; CDC: Centers for Disease Control; HOMA: homeostasis model assessment of insulin resistance score; PI: protease inhibitors; NNRTI: non-nucleoside reverse-transcriptase inhibitors; NRTI: nucleoside reverse-transcriptase inhibitors; IQR: inter-quartile range; IVDU: intravenous drug user.</p

Factors associated with severe fibrosis (F3–F4).

<p><i>Abbreviations</i>: ART: antiretroviral therapy; CDC: Centers for Disease Control; HOMA: homeostasis model assessment of insulin resistance score; PI: protease inhibitors; NNRTI: non-nucleoside reverse-transcriptase inhibitors; NRTI: nucleoside reverse-transcriptase inhibitors; IQR: inter-quartile range; IVDU: intravenous drug user.</p

Demographic and clinical data for the patients according to their HIV tropism.

<p><i>Abbreviations</i>: ART: antiretroviral therapy; CDC: Centers for Disease Control; HOMA: homeostasis model assessment of insulin resistance score; PI: protease inhibitors; NNRTI: non-nucleoside reverse-transcriptase inhibitors; NRTI: nucleoside reverse-transcriptase inhibitors; IQR: inter-quartile range; IVDU: intravenous drug user.</p

Factors associated with the presence of CXCR4-using viruses.

<p><i>Abbreviations</i>: ART: antiretroviral therapy; CDC: Centers for Disease Control; PI: protease inhibitors; NNRTI: non-nucleoside reverse-transcriptase inhibitors; NRTI: nucleoside reverse-transcriptase inhibitors; IQR: inter-quartile range; IVDU: intravenous drug user.</p

HCV RNA concentrations according to HIV-1 tropism.

<p>HCV RNA concentrations according to HIV-1 tropism.</p

Changes in liver stiffness according to HIV-1 tropism of the 34 patients in the longitudinal study (medians are indicated by bars).

<p>Changes in liver stiffness according to HIV-1 tropism of the 34 patients in the longitudinal study (medians are indicated by bars).</p

Breakdown of all donor samples positive with each enzyme immunoassay (EIA) kit and results of the <i>recom</i>Line immunodot.

<p>Breakdown of all donor samples positive with each enzyme immunoassay (EIA) kit and results of the <i>recom</i>Line immunodot.</p

Results of patient serum samples using the different anti-HEV IgG assays.

<p>Samples 1 to 15 were obtained from patients with documented HEV infection (positive HEV PCR); samples 16 to 20 were obtained from patients 4–14 months following the acute phase.</p

Reported OBEs according to month and occupation, 2008–2010, Ain shams University Hospital, Cairo.

<p>OBE: occupational blood exposure; HCW: healthcare worker.</p

Divergce of the NS5A-dup strain from wild-type strains.

<p>Ninety percent posterior probability tree inferred from BEAST analysis under the coalescent constant size model with a random relaxed uncorrelated lognormal clock. NS5A-dup strains are indicated in blue. All strains carrying two V3-domains show common ancestry.</p